{"id":"W3025106536","doi":"10.1016/j.msard.2020.102158","title":"Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS","year":2020,"lang":"en","type":"review","venue":"Multiple Sclerosis and Related Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Michael's Hospital","funders":"Actelion Pharmaceuticals; Genentech; Bayer Schering; IC Design Education Center; Alkermes; Alexion Pharmaceuticals; Genzyme; Biogen Idec; Patient-Centered Outcomes Research Institute; Celgene; Bayer; Biogen; Bayer HealthCare; Sanofi; Almirall; MedDay Pharmaceuticals; Merck; National Institute of Neurological Disorders and Stroke; Teva Pharmaceutical Industries; EMD Serono; Novartis; Roche; Pfizer","keywords":"Teriflunomide; Medicine; Multiple sclerosis; Tolerability; Adverse effect; Disease; Fingolimod; Intensive care medicine; Natalizumab; Internal medicine; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009777527,0.0008183553,0.003140642,0.002514055,0.0001813498,0.0009435181,0.0009640892,0.0009841134,0.00483887],"category_scores_gemma":[0.001515866,0.0002948784,0.001573961,0.002281964,0.0003435277,0.0008805728,0.0005415487,0.001239308,0.0005046726],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005891235,"about_ca_system_score_gemma":0.0009081829,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002050216,"about_ca_topic_score_gemma":0.004306639,"domain_scores_codex":[0.9997196,0.00007572778,0.00007404852,0.000041107,0.00006631649,0.0000232984],"domain_scores_gemma":[0.9993663,0.0004339219,0.0001285267,0.00000883358,0.00004206933,0.00002030498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0008633353,0.00007907404,0.0002403924,0.1937315,0.002123363,0.0001591548,0.00007763355,0.0002447803,0.001048351,0.00121651,0.01041741,0.7897985],"study_design_scores_gemma":[0.002625496,0.001545664,0.00656509,0.2109163,0.03126661,0.002772585,0.0003766051,0.0004325858,0.001379331,0.003307962,0.7386993,0.0001125265],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007809362,0.9997144,0.00001478256,0.0000317858,0.0000405664,0.000003831894,0.00001109329,0.000001463105,0.0001039353],"genre_scores_gemma":[0.001250901,0.9983774,0.00008263352,0.0001148943,0.00005317193,0.000007111084,0.00001975296,7.355094e-7,0.00009327116],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00483887,"threshold_uncertainty_score":0.01618767,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0781052675865193,"score_gpt":0.3177968576131146,"score_spread":0.2396915900265953,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}